Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-05-28
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound devices and related cloud software, AI, and partner-embedded imaging capabilities for clinicians and healthcare systems.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

More Than a Probe, Not Yet a Platform
The upside depends on turning a differentiated handheld ultrasound device into a broader workflow and Embedded imaging business. That can drive meaningful appreciation, but the next leg needs proof that newer revenue streams are repeatable rather than milestone-driven.

Analysis

Thesis
The 5-year upside is not just more probe sales; it is proving that Butterfly’s regulated ultrasound-on-chip stack can expand into enterprise workflow, Embedded royalties, and distributed-care imaging, creating a higher-margin business that is still hardware-anchored but no longer valued like a single-product device vendor.
Last Economy Alignment
Cheaper AI should widen ultrasound adoption, while Butterfly still controls regulated hardware, workflow embedment, and API permissioning that are harder to commoditize.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
This setup supports meaningful upside, but not an open-ended re-rating. Butterfly already has a shipping product, improving gross margin, cash on hand, and several credible second acts. The key question is whether newer layers become repeatable enough to change business quality. I assume some multiple compression from today’s option value, offset by stronger revenue mix and scale. That makes execution on revenue growth more important than heroic valuation expansion.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not product validity; Butterfly already has that. The real question is whether higher-margin layers such as Embedded, enterprise workflow, and home/community care become repeatable before larger imaging vendors neutralize the software edge. If those layers stay concentrated, milestone-driven, or hard to prove economically, Butterfly can still grow, but it will likely be valued more like a niche device company than a broader imaging platform.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.40
They control the probe, the chip architecture, and the permissions around who can build on top of it, so AI can expand usage without making the core device obsolete. The risk is that bigger imaging vendors bundle similar handheld tools and Butterfly’s newer software layers do not become sticky fast enough.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.69
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case